Nursing and Pharmacy Coordination in Metastatic Pancreatic Ductal Adenocarcinoma Care

This segment highlights the central role of multidisciplinary coordination in the safe and effective management of patients receiving Nalirifox for metastatic pancreatic ductal adenocarcinoma. Faculty discuss how close collaboration between physicians, nursing teams, and pharmacists supports early identification of toxicities, timely dose adjustments, and consistent delivery of supportive care throughout treatment.

Panelists describe how nursing teams are often the first to recognize emerging adverse events through patient communication, symptom assessment, and routine follow up. Early recognition allows for prompt intervention, which can prevent escalation of toxicity and reduce the risk of unplanned treatment delays or discontinuation. Pharmacy teams play a complementary role by assisting with dose verification, supportive medication selection, and education related to regimen specific toxicities.

The discussion emphasizes the importance of clear communication practices and coordinated workflows that allow care teams to respond efficiently to patient needs. Faculty highlight practical approaches such as pre treatment education, clear escalation protocols, and regular interdisciplinary check ins to ensure alignment across the care team.

By fostering proactive coordination, clinicians are better equipped to maintain treatment continuity while prioritizing patient safety. This segment reinforces that successful delivery of Nalirifox in metastatic pancreatic ductal adenocarcinoma depends not only on clinical decision making, but also on strong teamwork and shared responsibility across disciplines.